Literature DB >> 23519521

Successful long-term outcome after renal transplantation in a patient with atypical haemolytic uremic syndrome with combined membrane cofactor protein CD46 and complement factor I mutations.

Werner Lukas Pabst1, Thomas J Neuhaus, Samuel Nef, Elena Bresin, Andrea Zingg-Schenk, Giuseppina Spartà.   

Abstract

BACKGROUND: Atypical haemolytic uremic syndrome (aHUS) is often associated with a high risk of disease recurrence and subsequent graft loss after isolated renal transplantation. Evidence-based recommendations for a mutation-based management after renal transplantation in aHUS caused by a combined mutation with complement factor I (CFI) and membrane cofactor protein CD46 (MCP) are limited. CASE-DIAGNOSIS/TREATMENT: We describe a 9-year-old boy with a first manifestation of aHUS at the age of 9 months carrying combined heterozygous mutations in the CFI and MCP genes. At the age of 5 years, he underwent isolated cadaveric renal transplantation. Fresh frozen plasma was administered during and after transplantation, tapered and finally stopped after 3 years.
CONCLUSIONS: During the 5-year follow-up after transplantation there have been no signs of aHUS recurrence and graft function has remained good. The combination of heterozygous MCP and CFI mutations with aHUS might have a positive impact on the post-transplant course, possibly predicting a lower risk of aHUS recurrence after an isolated cadaveric renal transplantation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519521     DOI: 10.1007/s00467-013-2450-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  18 in total

1.  Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor.

Authors:  Rosemary L Donne; Ian Abbs; Peter Barany; Carl-Gustaf Elinder; Mark Little; Peter Conlon; Timothy H J Goodship
Journal:  Am J Kidney Dis       Date:  2002-12       Impact factor: 8.860

Review 2.  Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.

Authors:  Jeffrey M Saland; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

Review 3.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

4.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

5.  Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Elizabeth J Kemp; Elizabeth Mayland; Robin J Winney; Jeremy S Duffield; Graham Warwick; Anna Richards; Roy Ward; Judith A Goodship; Timothy H J Goodship
Journal:  J Am Soc Nephrol       Date:  2005-05-25       Impact factor: 10.121

6.  Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP.

Authors:  J M Cruzado; S Rodríguez de Córdoba; E Melilli; O Bestard; I Rama; P Sánchez-Corral; M López-Trascasa; I Navarro; J Torras; M Gomà; J M Grinyó
Journal:  Am J Transplant       Date:  2009-05-20       Impact factor: 8.086

7.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

8.  Three cases of factor I deficiency: the effect of treatment with plasma.

Authors:  J Møller Rasmussen; B Teisner; H H Jepsen; S E Svehag; F Knudsen; H Kirstein; M Buhl
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

9.  Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics.

Authors:  Lianne M Geerdink; Dineke Westra; Joanna A E van Wijk; Eiske M Dorresteijn; Marc R Lilien; Jean-Claude Davin; Martin Kömhoff; Koen Van Hoeck; Amerins van der Vlugt; Lambertus P van den Heuvel; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2012-03-13       Impact factor: 3.714

10.  Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome.

Authors:  David Kavanagh; Anna Richards; Marina Noris; Richard Hauhart; M Kathryn Liszewski; Diana Karpman; Judith A Goodship; Veronique Fremeaux-Bacchi; Giuseppe Remuzzi; Timothy H J Goodship; John P Atkinson
Journal:  Mol Immunol       Date:  2007-06-26       Impact factor: 4.407

View more
  3 in total

Review 1.  Primary disease recurrence—effects on paediatric renal transplantation outcomes.

Authors:  Justine Bacchetta; Pierre Cochat
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314

Review 2.  Complement regulator CD46: genetic variants and disease associations.

Authors:  M Kathryn Liszewski; John P Atkinson
Journal:  Hum Genomics       Date:  2015-06-10       Impact factor: 4.639

3.  CD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells modulates complement activation.

Authors:  Matthias Wieser; Teresa Francisci; Daniel Lackner; Tilmann Buerckstuemmer; Kamilla Wasner; Wolf Eilenberg; Anton Stift; Markus Wahrmann; Georg A Böhmig; Johannes Grillari; Regina Grillari-Voglauer
Journal:  PLoS One       Date:  2019-04-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.